These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9916114)

  • 1. Role of lipopolysaccharide sialylation in serum resistance of serogroup B and C meningococcal disease isolates.
    Vogel U; Claus H; Heinze G; Frosch M
    Infect Immun; 1999 Feb; 67(2):954-7. PubMed ID: 9916114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The (alpha2-->8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum.
    Kahler CM; Martin LE; Shih GC; Rahman MM; Carlson RW; Stephens DS
    Infect Immun; 1998 Dec; 66(12):5939-47. PubMed ID: 9826376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of an isogenic meningococcal alpha-2,3-sialyltransferase mutant: the role of lipooligosaccharide sialylation for serum resistance in serogroup B meningococci.
    Vogel U; Claus H; Heinze G; Frosch M
    Med Microbiol Immunol; 1997 Oct; 186(2-3):159-66. PubMed ID: 9403845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis.
    Vogel U; Weinberger A; Frank R; Müller A; Köhl J; Atkinson JP; Frosch M
    Infect Immun; 1997 Oct; 65(10):4022-9. PubMed ID: 9317002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Neisseria lipooligosaccharide-specific alpha-2,3-sialyltransferase is a surface-exposed outer membrane protein.
    Shell DM; Chiles L; Judd RC; Seal S; Rest RF
    Infect Immun; 2002 Jul; 70(7):3744-51. PubMed ID: 12065517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the length of the lipooligosaccharide alpha chain on its sialylation in Neisseria meningitidis.
    Tsai CM; Kao G; Zhu P
    Infect Immun; 2002 Jan; 70(1):407-11. PubMed ID: 11748209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose.
    Estabrook MM; Griffiss JM; Jarvis GA
    Infect Immun; 1997 Nov; 65(11):4436-44. PubMed ID: 9353017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing.
    Kugelberg E; Gollan B; Tang CM
    Vaccine; 2008 Dec; 26 Suppl 8(6):I34-9. PubMed ID: 19388162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells.
    Unkmeir A; Kämmerer U; Stade A; Hübner C; Haller S; Kolb-Mäurer A; Frosch M; Dietrich G
    Infect Immun; 2002 May; 70(5):2454-62. PubMed ID: 11953382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Lst Sialyltransferase of Neisseria gonorrhoeae Can Transfer Keto-Deoxyoctanoate as the Terminal Sugar of Lipooligosaccharide: a Glyco-Achilles Heel That Provides a New Strategy for Vaccines to Prevent Gonorrhea.
    Jen FE; Ketterer MR; Semchenko EA; Day CJ; Seib KL; Apicella MA; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33758087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the gene cassette required for biosynthesis of the (alpha1-->6)-linked N-acetyl-D-mannosamine-1-phosphate capsule of serogroup A Neisseria meningitidis.
    Swartley JS; Liu LJ; Miller YK; Martin LE; Edupuganti S; Stephens DS
    J Bacteriol; 1998 Mar; 180(6):1533-9. PubMed ID: 9515923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-2,3-sialyltransferase expression level impacts the kinetics of lipooligosaccharide sialylation, complement resistance, and the ability of Neisseria gonorrhoeae to colonize the murine genital tract.
    Lewis LA; Gulati S; Burrowes E; Zheng B; Ram S; Rice PA
    mBio; 2015 Feb; 6(1):. PubMed ID: 25650401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease.
    Hammerschmidt S; Müller A; Sillmann H; Mühlenhoff M; Borrow R; Fox A; van Putten J; Zollinger WD; Gerardy-Schahn R; Frosch M
    Mol Microbiol; 1996 Jun; 20(6):1211-20. PubMed ID: 8809773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies.
    Uria MJ; Zhang Q; Li Y; Chan A; Exley RM; Gollan B; Chan H; Feavers I; Yarwood A; Abad R; Borrow R; Fleck RA; Mulloy B; Vazquez JA; Tang CM
    J Exp Med; 2008 Jun; 205(6):1423-34. PubMed ID: 18504306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive potential of nonencapsulated disease isolates of Neisseria meningitidis.
    Johswich KO; Zhou J; Law DK; St Michael F; McCaw SE; Jamieson FB; Cox AD; Tsang RS; Gray-Owen SD
    Infect Immun; 2012 Jul; 80(7):2346-53. PubMed ID: 22508859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005.
    Harrison LH; Shutt KA; Schmink SE; Marsh JW; Harcourt BH; Wang X; Whitney AM; Stephens DS; Cohn AA; Messonnier NE; Mayer LW
    J Infect Dis; 2010 Apr; 201(8):1208-24. PubMed ID: 20199241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody Assays.
    Lucidarme J; Louth J; Townsend-Payne K; Borrow R
    Methods Mol Biol; 2019; 1969():169-179. PubMed ID: 30877677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mannose-binding lectin accelerates complement activation and increases serum killing of Neisseria meningitidis serogroup C.
    Jack DL; Jarvis GA; Booth CL; Turner MW; Klein NJ
    J Infect Dis; 2001 Oct; 184(7):836-45. PubMed ID: 11509995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor H and neisserial pathogenesis.
    Welsch JA; Ram S
    Vaccine; 2008 Dec; 26 Suppl 8(Suppl 8):I40-5. PubMed ID: 19388163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.
    Mountzouros KT; Belanger KA; Howell AP; Bixler GS; Madore DV
    Infect Immun; 2002 Dec; 70(12):6576-82. PubMed ID: 12438327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.